Teva Pharmaceutical (NYSE: TEVA) published its 2024 Healthy Future Report, highlighting significant sustainability achievements. The company surpassed several key targets ahead of schedule, including a 29% reduction in greenhouse gas emissions (exceeding 25% target) and launching nine access to medicine programs (surpassing target of eight). Teva donated approximately 18 million doses of medicine worth $23 million and provided 2.2 million doses at low cost, reaching 187,000 patients. The company achieved strong compliance metrics with 99% of employees trained on ethics and 41% of significant suppliers evaluated for sustainability. Teva's generic medicines contributed to $39.7 billion in healthcare savings across 22 countries. The company received improved sustainability scores from rating organizations, including its highest score from EcoVadis, demonstrating progress in environmental, social, and governance initiatives.
Teva Pharmaceutical (NYSE: TEVA) ha pubblicato il suo Rapporto Futuro Sano 2024, evidenziando importanti risultati in termini di sostenibilità. L'azienda ha superato in anticipo diversi obiettivi chiave, tra cui una riduzione del 29% delle emissioni di gas serra (oltre l'obiettivo del 25%) e il lancio di nove programmi di accesso ai farmaci (superando il target di otto). Teva ha donato circa 18 milioni di dosi di medicinali per un valore di 23 milioni di dollari e fornito 2,2 milioni di dosi a basso costo, raggiungendo 187.000 pazienti. L'azienda ha ottenuto eccellenti risultati in termini di conformità, con il 99% dei dipendenti formati sull'etica e il 41% dei fornitori significativi valutati per la sostenibilità. I farmaci generici di Teva hanno contribuito a 39,7 miliardi di dollari di risparmi sanitari in 22 paesi. L'azienda ha ricevuto punteggi migliorati da parte delle agenzie di rating sulla sostenibilità, incluso il suo punteggio più alto da EcoVadis, dimostrando progressi nelle iniziative ambientali, sociali e di governance.
Teva Pharmaceutical (NYSE: TEVA) publicó su Informe Futuro Saludable 2024, destacando importantes logros en sostenibilidad. La compañía superó varios objetivos clave antes de lo previsto, incluyendo una reducción del 29% en las emisiones de gases de efecto invernadero (superando la meta del 25%) y el lanzamiento de nueve programas de acceso a medicamentos (superando la meta de ocho). Teva donó aproximadamente 18 millones de dosis de medicamentos valoradas en 23 millones de dólares y proporcionó 2,2 millones de dosis a bajo costo, alcanzando a 187,000 pacientes. La empresa logró fuertes métricas de cumplimiento con el 99% de sus empleados capacitados en ética y el 41% de sus proveedores significativos evaluados en sostenibilidad. Los medicamentos genéricos de Teva contribuyeron a 39.7 mil millones de dólares en ahorros en salud en 22 países. La compañía recibió mejores puntuaciones de sostenibilidad por parte de organizaciones calificadoras, incluyendo su puntuación más alta de EcoVadis, demostrando avances en iniciativas ambientales, sociales y de gobernanza.
테바 제약회사(NYSE: TEVA)는 2024 건강한 미래 보고서를 발표하며 중요한 지속 가능성 성과를 강조했습니다. 회사는 온실가스 배출량을 29% 감축(목표 25% 초과)하고, 9개의 의약품 접근 프로그램(목표 8개 초과)을 출시하는 등 여러 핵심 목표를 예정보다 앞서 달성했습니다. 테바는 약 1,800만 회분의 의약품(가치 2,300만 달러)을 기부하고, 220만 회분을 저렴한 가격에 제공하여 18만 7천 명의 환자에게 도달했습니다. 직원의 99%가 윤리 교육을 이수했으며, 주요 공급업체의 41%가 지속 가능성 평가를 받는 등 높은 준수 지표를 기록했습니다. 테바의 제네릭 의약품은 22개국에서 397억 달러의 의료비 절감에 기여했습니다. 또한 EcoVadis를 포함한 평가 기관들로부터 지속 가능성 점수가 향상되어 환경, 사회 및 거버넌스 분야에서 진전을 입증했습니다.
Teva Pharmaceutical (NYSE : TEVA) a publié son Rapport Avenir Sain 2024, mettant en lumière des réalisations importantes en matière de durabilité. L'entreprise a dépassé plusieurs objectifs clés avant l'échéance, notamment une réduction de 29 % des émissions de gaz à effet de serre (au-delà de l'objectif de 25 %) et le lancement de neuf programmes d'accès aux médicaments (au-delà de l'objectif de huit). Teva a fait don d'environ 18 millions de doses de médicaments d'une valeur de 23 millions de dollars et fourni 2,2 millions de doses à bas coût, atteignant 187 000 patients. L'entreprise a obtenu d'excellents résultats en matière de conformité avec 99 % des employés formés à l'éthique et 41 % des fournisseurs importants évalués sur la durabilité. Les médicaments génériques de Teva ont contribué à 39,7 milliards de dollars d'économies de santé dans 22 pays. La société a reçu des scores de durabilité améliorés de la part des agences de notation, y compris son score le plus élevé d'EcoVadis, démontrant des progrès dans les initiatives environnementales, sociales et de gouvernance.
Teva Pharmaceutical (NYSE: TEVA) veröffentlichte ihren Bericht für eine gesunde Zukunft 2024, in dem bedeutende Nachhaltigkeitserfolge hervorgehoben werden. Das Unternehmen übertraf mehrere wichtige Ziele vorzeitig, darunter eine Reduktion der Treibhausgasemissionen um 29% (über dem Ziel von 25%) und die Einführung von neun Programmen für den Zugang zu Medikamenten (mehr als das Ziel von acht). Teva spendete ungefähr 18 Millionen Dosen Medikamente im Wert von 23 Millionen US-Dollar und stellte 2,2 Millionen Dosen zu niedrigen Kosten bereit, wodurch 187.000 Patienten erreicht wurden. Das Unternehmen erzielte starke Compliance-Werte mit 99% der Mitarbeiter, die in Ethik geschult wurden, und 41% der bedeutenden Lieferanten wurden auf Nachhaltigkeit bewertet. Die Generika von Teva trugen zu 39,7 Milliarden US-Dollar Einsparungen im Gesundheitswesen in 22 Ländern bei. Das Unternehmen erhielt verbesserte Nachhaltigkeitsbewertungen von Rating-Agenturen, darunter die höchste Bewertung von EcoVadis, was Fortschritte in Umwelt-, Sozial- und Governance-Initiativen zeigt.
Positive
Surpassed greenhouse gas emissions reduction target of 25% by achieving 29% reduction
Exceeded access to medicine programs target with nine programs, donating $23M worth of medicines
Generated $39.7B in healthcare savings across 22 countries through generic medicines
Achieved 99% employee compliance training completion rate
Received improved sustainability scores from major rating organizations
73% of applicable sites achieved safe discharge levels of antibiotics
Negative
Only 41% of significant suppliers were evaluated for sustainability performance
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule
Teva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025
More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability performance
Teva received improved scores for sustainability progress from rating organizations, including its highest score to date from EcoVadis
Teva’s generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2024 Healthy Future Report, sharing actions to advance its sustainability strategy. Teva achieved or surpassed many of its targets, some ahead of schedule. This includes targets tied to sustainable finance instruments, which directly connect its progress in increasing access to medicines and minimizing environmental impact to the Company’s financial success. Healthy Future is focused on topics most relevant to Teva’s business, supporting the Company in advancing its purpose—we are all in for better health—and enhancing its resilience.
Healthy People Teva launched two new access to medicines programs—one in El Salvador and a global emergency stockpile—for a total of nine, surpassing its target of eight programs by 2025. Through these nine programs, Teva donated ~18 million doses of medicine, worth $23 million, and provided 2.2 million doses at low cost, reaching 187,000 patients. Five programs also focus on health systems strengthening and capacity building and benefitted ~56,000 individuals.
Healthy Planet Teva achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas (GHG) emissions from 2019 levels, surpassing its target of 25% by 2025 ahead of schedule. Additionally, 73% of applicable Teva sites achieved safe discharge levels of antibiotics, minimizing environmental pollution and supporting public health. Through a new antimicrobial resistance capacity-building pilot program in Germany, the Company educated more than 65,000 healthcare professionals, leading to approximately 389,000 patient interactions about appropriate use of antibiotics.
Healthy Business Operating with integrity helps Teva mitigate risk and build trust with its stakeholders. More than 99% of employees were retrained on compliance and ethics and Teva’s Code of Conduct, achieving its annual target and reinforcing a culture of accountability and ethical decision-making. 41% of significant suppliers were evaluated for sustainability performance, and 100% of high-risk third-party business partners were evaluated through Teva’s Third-Party Due Diligence tool, ensuring responsible sourcing practices and reducing risks across its supply chain.
“Healthy Future is closely connected to our Pivot to Growth strategy, designed to support long-term growth and resilience” said Richard Francis, Teva’s President and CEO. “Our 2024 Healthy Future report shares how we’re advancing the topics most closely tied to our business, strengthening our company while continuing to better health worldwide—to create the future we want to see.”
Teva received improved scores from rating organizations such as Sustainalytics, MSCI and EcoVadis, as well as awards and recognition for its programs and progress.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our sustainability, social, economic, environment and governance related strategies and goals; environmental risks; failure to comply with applicable environmental laws, health and safety laws and regulations worldwide; our ability to select sustainability-related disclosure frameworks that seek to align with various reporting standards which may change from time to time; our ability to collect, measure and report sustainability information and metrics, which is subject to evolving reporting standards; our ability to satisfy the targets set forth in our sustainability-linked senior notes, our sustainability-linked revolving credit facility and in other sustainability-linked financing instruments that we may issue; the impact of sustainability issues and other environmental risks on our business; and consequences of climate change; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
What sustainability targets did TEVA achieve in its 2024 Healthy Future Report?
TEVA achieved a 29% reduction in greenhouse gas emissions (surpassing 25% target), launched nine access to medicine programs (exceeding target of eight), and achieved 99% employee compliance training completion.
How much did TEVA's generic medicines save healthcare systems in 2024?
TEVA's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries.
What was TEVA's medicine donation impact in 2024?
TEVA donated approximately 18 million doses of medicine worth $23 million and provided 2.2 million doses at low cost, reaching 187,000 patients.
How is TEVA addressing environmental sustainability in its operations?
TEVA achieved a 29% reduction in greenhouse gas emissions from 2019 levels and ensured 73% of applicable sites achieved safe discharge levels of antibiotics.
What progress has TEVA made in supplier sustainability evaluation?
TEVA evaluated 41% of significant suppliers for sustainability performance and assessed 100% of high-risk third-party business partners through its Due Diligence tool.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
